Browse Studies — Arctuva

Phase 1

A Phase I Study of Bivalent CD79b and CD19 Directed CAR T Cells in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma

This research study involves the study of CD79b-19 CAR T cells for treating people with relapsed/refractory Non-Hodgkin Lymphoma and to understand the side eff…

Non-hodgkin LymphomaRelapsed Non-Hodgkin LymphomaRefractory Non-Hodgkin Lymphoma+7 more

Estimated

~$10 – $7,500

Marcela V. Maus, M.D.,Ph.D.NCT06026319

Phase 1

Phase I/II Study of Tandem, Bispecific Anti-CD19 Anti-CD20 CAR-T Cells for Patients With Relapsed and/or Refractory B Cell Malignancies

This is a Phase I/II, interventional, single-arm, open-label, treatment study designed to evaluate the safety and efficacy of Interleukin-7 and Interleukin-15 …

Non Hodgkin Lymphoma (NHL)Mantle Cell Lymphoma (MCL)Chronic Lymphocytic Leukemia (CLL)+5 more

Estimated

~$10 – $6,250

Medical College of WisconsinNCT04186520

Phase 2

A Pilot Study of Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for Upfront Treatment of Aggressive B-Cell Non-Hodgkin Lymphomas

This phase II trial tests the safety, best dose, and effectiveness of epcoritamab when given with etoposide, cyclophosphamide, vincristine, doxorubicin, predni…

B-Cell Non-Hodgkin LymphomaBurkitt LymphomaDiffuse Large B-Cell Lymphoma, Not Otherwise Specified+6 more

Estimated

~$10 – $6,250

Phase 2

A Phase II Trial of Pembrolizumab in Combination With Chimeric Antigen Receptor Therapy in Patients With Relapsed/Refractory Primary Mediastinal B-cell Lymphoma

This research study is evaluating the combination of drugs, pembrolizumab with chimeric antigen receptor (CAR) T-cell therapy, as a possible treatment for prim…

Primary Mediastinal Large B-cell Lymphoma (PMBCL)Primary Mediastinal Large B Cell LymphomaPrimary Mediastinal Large B-Cell Lymphoma Refractory+3 more

Estimated

~$10 – $7,500

Jennifer Crombie, MDNCT05934448